Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIPELINE-RSV adaptive platform trial of maternal vaccine and infant monoclonal antibody for RSV prevention
NL-OMON59281Phase 3Recruiting
- Sponsor
- Penta Foundation
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of infant RSV monoclonal antibody in respiratory syncytial virus disease (RSV) (3 arms), sponsored by Penta Foundation. Started Jul 2026; status: recruiting.
02
Drugs
infant RSV monoclonal antibody
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on NL-OMON59281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59281.